Allergan announced the launch of Saphris (asenapine) 2.5mg sublingual tablets as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients aged 10–17 years.
Saphris, a second generation atypical antipsychotic, is also indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy or as adjunctive therapy with either lithium or valproate. The efficacy of asenapine may be mediated through a combination of antagonist activity at D2 and 5-HT2A receptors.
Saphris for pediatric patients is available in 2.5mg sublingual black cherry flavored tablets.
For more information call (800) 678-1605 or visit Saphris.com.